Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 379501, 8 pages
http://dx.doi.org/10.1155/2015/379501
Research Article

Effect of Oral and Vaginal Hormonal Contraceptives on Inflammatory Blood Biomarkers

1Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA
3Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
4Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
5Blood and Marrow Transplantation Division, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA

Received 17 December 2014; Accepted 16 February 2015

Academic Editor: Amedeo Amedei

Copyright © 2015 Afshin A. Divani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kanda and T. Takahashi, “Interleukin-6 and cardiovascular diseases,” Japanese Heart Journal, vol. 45, no. 2, pp. 183–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Ballantyne and V. Nambi, “Markers of inflammation and their clinical significance,” Atherosclerosis Supplements, vol. 6, no. 2, pp. 21–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kaptoge, E. di Angelantonio, L. Pennells, A. M. Wood, I. R. White, and P. Gao, “C-reactive protein, fibrinogen, and cardiovascular disease prediction,” The New England Journal of Medicine, vol. 367, pp. 1310–1320, 2012. View at Google Scholar
  8. J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Verma, M. A. Kuliszewski, S. H. Li et al., “C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease,” Circulation, vol. 109, no. 17, pp. 2058–2067, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. W. Zieske, R. P. Tracy, C. A. McMahan et al., “Elevated serum C-reactive protein levels and advanced atherosclerosis in youth,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 6, pp. 1237–1243, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-L. Chei, K. Yamagishi, A. Kitamura et al., “C-reactive protein levels and risk of stroke and its subtype in Japanese: the Circulatory Risk in Communities Study (CIRCS),” Atherosclerosis, vol. 217, no. 1, pp. 187–193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. S. Merki-Feld, M. Rosselli, B. Imthurn, and K. Spanaus, “No effect of Implanon on inflammatory cardiovascular parameters,” Gynecological Endocrinology, vol. 27, no. 11, pp. 951–955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. W. K. Lagrand, C. A. Visser, W. T. Hermens et al., “C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon?” Circulation, vol. 100, no. 1, pp. 96–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. J.-J. Li and C.-H. Fang, “C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases,” Medical Hypotheses, vol. 62, no. 4, pp. 499–506, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Bassuk, N. Rifai, and P. M. Ridker, “High-sensitivity C-reactive protein: clinical importance,” Current Problems in Cardiology, vol. 29, no. 8, pp. 439–493, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Buchbinder, J. Kratzsch, G. M. Fiedler et al., “Body weight and oral contraceptives are the most important modulators of serum CRP levels,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 2, pp. 140–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Cauci, M. Di Santolo, J. F. Culhane, G. Stel, F. Gonano, and S. Guaschino, “Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women,” Obstetrics & Gynecology, vol. 111, no. 4, pp. 857–864, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Silvestri, O. Gebara, C. Vitale et al., “Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response,” Circulation, vol. 107, no. 25, pp. 3165–3169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. van Rooijen, L. O. Hansson, J. Frostegård, A. Silveira, A. Hamsten, and K. Bremme, “Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 77–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Kluft, J. A. G. Leuven, F. M. Helmerhorst, and H. M. J. Krans, “Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment,” Vascular Pharmacology, vol. 39, no. 3, pp. 149–154, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Duijkers, S. Killick, A. Bigrigg, and T. O. M. Dieben, “A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function,” The European Journal of Contraception and Reproductive Health Care, vol. 9, no. 3, pp. 131–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. Timmer and T. M. Mulders, “Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring,” Clinical Pharmacokinetics, vol. 39, no. 3, pp. 233–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. K. R. Brandy, R. M. Meyer, X. Luo, G. H. Rao, Y. H. Datta, and A. A. Divani, “Evaluation of the coagulation profile among oral and vaginal combined hormonal contraceptive users using sonoclot coagulation analyzer,” Clinical and Applied Thrombosis/Hemostasis, vol. 18, no. 6, pp. 576–581, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. A. Divani, X. Luo, K. R. Brandy et al., “Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women,” Clinical and Applied Thrombosis/Hemostasis, vol. 18, no. 5, pp. 487–494, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Libby and P. M. Ridker, “Inflammation and atherosclerosis: role of C-reactive protein in risk assessment,” The American Journal of Medicine, vol. 116, no. 6, pp. 9–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Welsh, M. Woodward, A. Rumley, and G. Lowe, “Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study,” British Journal of Haematology, vol. 141, no. 6, pp. 852–861, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Woodward, A. Rumley, G. D. O. Lowe, and H. Tunstall-Pedoe, “C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease,” British Journal of Haematology, vol. 122, no. 1, pp. 135–141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. Eklund, “Chapter 5 Proinflammatory cytokines in CRP baseline regulation,” Advances in Clinical Chemistry, vol. 48, pp. 111–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Piltonen, J. Puurunen, P. Hedberg et al., “Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study,” Human Reproduction, vol. 27, no. 10, pp. 3046–3056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Rad, J. Burggraaf, R. L. Sitruk-Ware, M. L. De Kam, A. F. Cohen, and C. Kluft, “Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein,” Steroids, vol. 77, no. 13, pp. 1483–1486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. D. O. Lowe, M. N. Upton, A. Rumley, A. McConnachie, D. S. J. O'Reilly, and G. C. M. Watt, “Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey,” Thrombosis and Haemostasis, vol. 86, no. 2, pp. 550–556, 2001. View at Google Scholar · View at Scopus
  33. G. D. Norata, C. Garlanda, and A. L. Catapano, “The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases,” Trends in Cardiovascular Medicine, vol. 20, no. 2, pp. 35–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Wang, W. Jin, A. M. Guo, and J. Stubbe, “Cardiovascular inflammation,” Mediators of Inflammation, vol. 2013, Article ID 123513, 2 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Zhou, J. Chen, T. H. Rissanen et al., “Outcome-dependent sampling: an efficient sampling and inference procedure for studies with a continuous outcome,” Epidemiology, vol. 18, no. 4, pp. 461–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. J. V. Patel, S. L. Hoong, S. Nadar, M. Tayebjee, E. A. Hughes, and G. Y. H. Lip, “Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis,” Journal of Hypertension, vol. 24, no. 1, pp. 117–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Heeschen, S. Dimmeler, C. W. Hamm et al., “Soluble CD40 ligand in acute coronary syndromes,” The New England Journal of Medicine, vol. 348, no. 12, pp. 1104–1111, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Ferro, L. Loffredo, L. Polimeni et al., “Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2763–2768, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. U. Schönbeck, N. Varo, P. Libby, J. Buring, and P. M. Ridker, “Soluble CD40L and cardiovascular risk in women,” Circulation, vol. 104, no. 19, pp. 2266–2268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. T. J. Wang, M. G. Larson, D. Levy et al., “C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study,” Circulation, vol. 106, no. 10, pp. 1189–1191, 2002. View at Publisher · View at Google Scholar · View at Scopus